What is Angion Biomedica Corp. (ANGN)?

Angion Biomedica Corp. (ANGN) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ANGN?

The current price of ANGN is $1.00. Prices are updated in real time on Stocks360.

What is ANGN's price-to-earnings (PE) ratio?

ANGN's trailing twelve-month PE ratio is -0.47, based on current price and earnings per share data available on Stocks360.

What is ANGN's market capitalization?

ANGN's market capitalization is $30,113,700.00, placing it in the small-cap tier.

Angion Biomedica Corp. (ANGN)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$1.00

Market Cap

$30.11M

PE (TTM)

-0.47

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.60

Day Range

$1.00 – $1.00

52-wk Range

$1.00 – $20.40

Avg Volume

N/A

Volume

224.80K

Angion Biomedica Corp. (ANGN) is a publicly traded company in the Healthcare sector. Latest price: $1.00. Market cap $30.11M. Trailing PE -0.47. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 21, 2023

EPS $-2.44 vs est. $0.57

Missed by $3.01

Proprietary Signals

Signal snapshot temporarily unavailable.

About Angion Biomedica Corp.

Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.47×
P/S (TTM)	0.00×
P/B	2.42×
P/FCF (TTM)	-0.80×
EV / EBITDA	-0.42×
EV / Sales	0.00×
Earnings Yield	-196.63%
Free Cash Flow Yield	-125.22%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$11.25M
Net Income (TTM)	-$59.21M
Free Cash Flow (TTM)	-$38.44M
Net Debt	-$18.87M
Working Capital	$16.28M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-1266.43%
Return on Invested Capital	-163.43%